Cheryl R. Blanchard
Chairman
Anika Therapeutics, Inc. (ANIK)Board Member
Anika Therapeutics, Inc. (ANIK)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Cheryl R. Blanchard
Cheryl R. Blanchard is recorded as Chairman and Board Member at Anika Therapeutics, Inc. (ANIK). Anika Therapeutics, Inc. reported in an 8-K filed January 8, 2026 that Cheryl R. Blanchard was appointed Executive Chair, effective February 1, 2026. Anika Therapeutics, Inc. reported in an 8-K filed June 24, 2025 that Cheryl R. Blanchard was appointed Class II director, effective June 20, 2025. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $4,887,318 for Cheryl R. Blanchard in fiscal 2025, including a base salary of $750,397. Disclosed compensation is on record for 8 fiscal years.
“Dr. Blanchard will transition into the role of Executive Chair of the Company's Board of Directors ("Board") for a period of twelve (12) months through January 31, 2027.”
“As a result of this vote, Dr. Blanchard, Mr. Capper and Dr. Larsen were elected as Class II directors to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until his or her earlier resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-02-01–present
-
Current
2018-01-01–present
-
Anika Therapeutics, Inc. (ANIK)
Proxy statement
CurrentStart not stated–present
-
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Anika Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Cheryl Blanchard CEO, Board Member
- Stephen (Steve) Griffin CEO, Board Member
- Stephen D. Griffin CEO, CFO, Board Member
- Steve Griffin CEO, Board Member
- Jeffery S. Thompson Chairman
- John B. Henneman, III Chairman, Board Member
- Michael Levitz CFO
- Stephen Griffin CFO
- Anne Nunes COO
- David B. Colleran General Counsel
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Anika Therapeutics, Inc. (ANIK) | Executive Chair; Former President and Chief Executive Officer | $750,397 | $4,887,318 |
| 2024 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $743,943 | $5,103,466 |
| 2023 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $726,000 | $4,459,800 |
| 2022 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $695,100 | $5,940,722 |
| 2021 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $668,400 | $4,202,608 |
| 2020 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $548,077 | $10,029,434 |
| 2019 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | — | — |
| 2018 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.